BOVNF (BioInvent International AB) Risk Assessment


BOVNF BioInvent International AB BOVNF
39 GF Score
Price $3.29
GF Value $7.07
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BioInvent International AB is: No Data: Cannot be evaluated.

BioInvent International AB  (OTCPK:BOVNF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BioInvent International AB Risk Assessment Related Terms

BOVNF vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, BioInvent International AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Risk Assessment falls into.


BOVNF
39GF Score
BioInvent International AB BOVNF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of $3.29 is trading 53.5% below its estimated GF Value™ of $7.07.

Key valuation signals for BOVNF:

  • Risk Assessment:
  • GF Value™: $7.07 vs. price of $3.29 (53.5% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score

Get the complete analysis for BOVNF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$7.07
GF Value